GlassScriptPhysician profile
Alexander W Kulischenko
NPI 1447204565
$1,732.81
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $695 · 2020: $755 · 2021: $283.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $400.51 | 2019-2021 | |
| Allergan, INC. | $311.76 | 2019-2020 | |
| Novo Nordisk INC | $169.50 | 2019-2021 | |
| Amarin Pharma, INC. | $148.59 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $124.00 | 2019 | |
| Kyowa Kirin, INC. | $121.54 | 2019 | |
| Abbott Laboratories | $118.81 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $97.31 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $75.50 | 2021 | |
| Merck Sharp & Dohme LLC | $63.77 | 2020-2021 | |
| Daiichi Sankyo INC. | $14.88 | 2021 | |
| Alexion Pharmaceuticals, INC. | $14.82 | 2020 | |
| Kaleo, INC. | $12.83 | 2019 | |
| Glaxosmithkline, LLC. | $12.21 | 2019 | |
| Biodelivery Sciences International, INC. | $11.99 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $11.88 | 2019 | |
| Antares Pharma, INC. | $11.62 | 2020 | |
| Abbvie INC. | $11.29 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Kulischenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.